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ABSTRACT ()–Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the ﬁrst compound found to have
dual function as a dopamine receptor D1 agonist and D2 antagonist. Insights into dynamical behaviors of D1 and D2 receptors
and their interaction modes with SPD are crucial in understanding the structural and functional characteristics of dopamine
receptors. In this study a computational approach, integrating protein structure prediction, automated molecular docking, and
molecular dynamics simulations were employed to investigate the dual action mechanism of SPD on the D1 and D2 receptors,
with the eventual aim to develop new drugs for treating diseases affecting the central nervous system such as schizophrenia.
The dynamics simulations revealed the surface features of the electrostatic potentials and the conformational ‘‘open-closed’’
process of the binding entrances of two dopamine receptors. Potential binding conformations of D1 and D2 receptors were
obtained, and the D1-SPD and D2-SPD complexes were generated, which are in good agreement with most of experimental
data. The D1-SPD structure shows that the K-167_EL-2-E-302_EL-3 (EL-2: extracellular loop 2; EL-3: extracellular loop 3) salt
bridge plays an important role for both the conformational change of the extracellular domain and the binding of SPD. Based on
our modeling and simulations, we proposed a mechanism of the dual action of SPD and a subsequent signal transduction
model. Further mutagenesis and biophysical experiments are needed to test and improve our proposed dual action mechanism
of SPD and signal transduction model.
INTRODUCTION
During the last decade, numerous efforts have been under-
taken to discover drugs for treating psychomotor diseases,
including the debilitating mental illness schizophrenia,
which affects 0.5–1.5% of the worldwide population (1–4).
It has been established that dopamine receptors (DRs) are
primary targets for developing drugs to treat these diseases.
DRs belong to the G-protein coupled receptor (GPCR)
superfamily, transferring signals into cells through guanine
nucleotide-binding regulatory G-proteins (4). The DRs can
be classiﬁed into two major subfamilies, D1 and D2 re-
ceptors, according to their structural, pharmacological, and
functional characteristics (4). Their functional domains
have been deﬁned, and the binding-site crevices have been
identiﬁed by the substituted-cysteine-accessibility method
(5–7). Although some studies revealed the structural fea-
tures of D1 and D2 receptors that underlie their partic-
ular biophysical and pharmacological properties (6,8),
many problems still remain unresolved due to experi-
mental limitations and the lack of three-dimensional (3D)
structures.
Antagonists of the D2 receptor are believed to be potential
drugs against the psychomotor diseases (9). Unfortunately,
these antagonists (e.g., the neuroleptic haloperidol) have
severe mechanism-related side effects, including induction
of acute extrapyramidal symptoms (EPS), tardive dyskinesia,
and problems of galactorrhea due to increase in prolactin
release (10). In contrast, atypical antipsychotics with less
EPS are effective in patients who are unresponsive to
classical agents and may also have advantages in treating the
more resistant negative symptoms of schizophrenia (10). The
use of atypical antipsychotics was, however, found to have a
high occurrence of a potentially fatal blood disorder called
agranulocytosis (10). Therefore, discovering effective, safe
antipsychotics remains a high priority (4,9,10).
The pathogenesis of schizophrenia was suggested to be
related to dysfunction of the D1 receptor in the medial pre-
frontal cortex (mPFC), which is accompanied by D2 receptor
hyperactivity in subcortical regions such as the ventral teg-
mental area (VTA) and the nucleus accumbens (NAc) (4).
The D1 dysfunction was suggested to be responsible for the
negative symptoms of schizophrenia, whereas the hyperactiv-
ity of the D2 receptor might lead to the positive symptoms of
this disorder (4,5,11). Based on this hypothesis, antipsychotic
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drugs with dual effect as a D1 receptor agonist and a D2
receptor antagonist would provide a new treatment for psy-
chotic diseases (4).
An active compound, namely ()–stepholidine (SPD),
isolated from the Chinese herb Stephania, is to date the only
drug with a dual effect as a D1 receptor agonist and a D2
receptor antagonist (4). SPD has high afﬁnity for D1- and
D2-like receptors but low afﬁnity for 5-HT2 receptors and
a2-adrenoceptors (4). The dual action of SPD has been dem-
onstrated in both cortical and subcortical structures, includ-
ing the mPFC, NAc, VTA, and basal ganglia dopamine
systems (4). Moreover, clinic studies showed that SPD is
superior to perphenazine in antipsychotic efﬁcacy. Unlike
perphenazine, SPD does not induce any EPSs (4), making
SPD an attractive compound in studying the dual action
mechanism of a chemical for developing novel antipsychotic
drugs. However, the molecular basis of the dual action of
SPD is obscure to date. Thus, exploring the dual action
mechanism of SPD against D1 and D2 receptors at the
atomic level is the ﬁrst step toward developing more superior
antipsychotic agents. Obviously, the 3D structures of D1 and
D2 receptors are essential to ﬁguring out the dual action
mechanism. Unfortunately, these 3D structures are not cur-
rently available.
It has been widely recognized that molecular modeling
and simulation are an excellent complement to experiments
in explaining experimental results and providing clues for
further experiments. Furthermore, it may reveal information
that is not accessible by experiments (12). Recently, great
success has been achieved in the ﬁeld of structure predic-
tion of GPCRs (13–15). For instance, some algorithms are
capable of predicting the transmembrane (TM) structures
(15–20). However, constructing appropriate conformational
states of the extracellular or intracellular domains of GPCRs
is still a tough job. Molecular dynamics (MD) simulations
(21), taking advantage of iteratively tracking the trajectory
of conformational change, could be used to simulate the
binding process, to explore the binding conformation, and to
map the binding mechanism at molecular and atomic levels.
To the best of our knowledge, no long timescale MD
simulation has been carried out so far on DRs. All this
motivates us to carry out a computational study on D1 and
D2 receptors to explore the mechanism of the dual action of
SPD on these two receptors. Thus, homology modeling,
automated molecular docking, and MD simulations have
been integrated in this study. A homology modeling
approach was used to construct 3D structures of D1 and
D2 receptors. Automated docking was used to ﬁnd possible
binding sites for SPD against the receptors. The MD sim-
ulations, performed in a fully hydrated lipid bilayer envi-
ronment, were carried out to address the following questions:
How does SPD bind to the D1 and D2 receptors? How does
SPD regulate the signal transduction of the D1 receptor?
What is the fundamental basis underlying the dual action of
SPD?
MODELING AND SIMULATION METHODS
Strategy of modeling and simulation
Experiments demonstrated that the sequences of aminergic receptors, viz.
dopamine, a-adrenergic, b-adrenergic, and serotonin receptors, are highly
conservative within the TM domains, which dictate the common ligand-
binding sites of these receptors (22). However, experimental data also
suggest that different binding interactions of ligands to one receptor lead to
different receptor conformations (10). The small changes in ligand structure
may affect its interactions with the receptor and, hence, the receptor activa-
tion (10). Thus, we faced two difﬁculties: 1), how to construct 3D models of
the D1 and D2 receptors, and 2), how to identify the binding conforma-
tions of the two receptors with SPD. To solve these problems, we integrated
several modeling and simulation methods in this study. The computational
pipeline is outlined in Fig. S1 in the Supplementary Material. Brieﬂy, the
computational ﬂow is as follows:
1. The 3D models of the D1 and D2 receptors were constructed using a
homology-modeling approach based on the x-ray crystal structure of
bovine rhodopsin.
2. Two 10-ns MD simulations were carried out respectively on the con-
structed D1 and D2 receptor models, embedded in a hydrated POPC
(palmitoyloleoylphosphatidylcholine) bilayer.
3. To ﬁnd the probable SPD binding conformations of D1 and D2 recep-
tors, SPD was docked into numerous minimum-energy conformations
isolated from the MD trajectories of the two receptors by using the mo-
lecular docking approach, including prediction of the binding free
energy between SPD and each selected conformation of the receptors.
Conformations of the two receptors with lowest binding free energies to
SPD were selected as the initial structures for further simulations.
4. Two additional 10-ns MD simulations were conducted on the initial
structures of SPD-D1 and SPD-D2 complexes, resulting from the above
docking calculations, embedded in a hydrated POPC bilayer.
5. The ligand-receptor interaction and the dual action mechanism of SPD
were explored by analyzing all of the modeling and simulation results.
Homology modeling for the 3D models of D1 and
D2 receptors
Bovine rhodopsin, a member of the GPCR superfamily, was structurally
determined at a resolution of 2.80 A˚ (Protein Data Bank entry 1F88) (17).
This x-ray structure of GPCRs provides a solid template for modeling the 3D
structures of other GPCRs (7). To obtain a reliable sequence alignment, 64
sequences of dopamine-type receptors downloaded from http://www.
gpcr.org/7tm were used. Residues were numbered according to the gener-
alized numbering scheme proposed by Ballesteros and Weinstein (22). To
facilitate the comparison among the aligned residues in various GPCRs, the
most conserved residue in transmembrane X is given the index number
X.50, and residues within a given TM are then indexed relative to the ‘‘50’’
position.
The MODELLER program encoded in InsightII (23) was employed to
assemble the 3D models of the a-helix bundles of D1 and D2 receptors by
using the x-ray crystal structure of bovine rhodopsin as a template. The
FASTA program (24) was used to identify sequence homology through an
in-house database (15) containing 700 loops and proteins with medium to
high sequence identity. ClustalW (25) was then used to determine the
fragments that have higher homology with the loops of D1 and D2 receptors.
A reasonable fragment conformation was chosen from the top 10 candidates
that have the lowest root mean-square (RMS) values and considerable
geometrical compatibility. The conserved disulﬁde bond between residues
Cys-3.25 at the beginning of TM III and Cys_EL-2 in the middle of
extracellular loop 2 (EL-2) was also created. Energy minimizations of the
models were carried out using the Discover module encoded in InsightII
with the same parameters as that of our previous studies (12).
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Molecular dynamics simulations
The MD simulations were performed using the GROMACS package ver-
sion 3.1.4 with the GROMOS96 force ﬁeld. (26,27) (www.gromacs.org).
The molecular topology ﬁle for SPD was generated with PRODRG (28)
(http://davapc1.bioch.dundee.ac.uk/programs/prodrg/prodrg.html). The par-
tial atomic charges of SPD were determined by using the CHelpG method
(29) implemented in the Gaussian98 program (30) with the DFT/B3LYP/
6-311G** basis set. For MD simulations, the four models (unliganded D1,
unliganded D2, SPD-D1, and SPD-D2 complexes) were embedded in a
hydrated POPC lipid bilayer. The procedure and parameters for constructing
the receptor/hydrated POPC systems are similar to those used in previous
membrane protein simulations (31–33). Fig. 1 shows, taking the SPD-D1
complex as an example, the structural model of the receptor/POPC/water
systems. Before MD simulations, energy minimizations were performed on
the four receptor/hydrated POPC systems ﬁrst for all water molecules to
remove their poor contacts with protein atoms, then for the whole system
until the maximum force was ,10.00 kcal/mol-A˚.
The solvent (water and POPC) molecules of each initial system were
equilibrated with protein structures by constraining the solute (D1 or D2) at
300 K for 20 ps. Then the protein was equilibrated for 5 ps and the solvent
molecules were constrained at 10, 50, 100, 200, and 298 K. Afterward, each
system was equilibrated for 250 ps without any constraints. To maintain the
systems at a constant temperature of 300 K, the Berendsen thermostat (34)
was applied using a coupling time of 0.1 ps for the bulk water and POPC.
The pressure was maintained by coupling to a reference pressure of 1 bar.
The values of the anisotropic isothermal compressibility were set to 4.5 3
105, 4.53 105, 4.53 105, 0, 0, 0 bar1 for xx, yy, zz, xy/yx, xz/zx, and
yz/zy components, respectively, for water and POPC simulations. The
lengths of all bonds, including those to hydrogen atoms, were constrained by
the LINCS algorithm (26). Electrostatic interactions between charged groups
within 9 A˚ were calculated explicitly, and long-range electrostatic interac-
tions were calculated using the particle mesh Ewald method (35) with a grid
width of 1.2 A˚ and a fourth-order spline interpolation. A cutoff distance of
14 A˚ was applied for the Lennard-Jones interactions. Numerical integration
of the equations of motion used a time step of 2 fs with atomic coordinates
saved every 1 ps for later analysis. To neutralize the modeled systems, 13, 9,
12, and 8 Cl ions were added to the molecular systems of the free D1, D2,
SPD-D1, and SPD-D2 complexes, respectively. Finally, four 10-ns MD
simulations were performed on these systems under the periodic boundary
conditions in the NPT canonical ensemble.
Molecular docking and binding energy calculation
The geometry of the SPD ligand was built based on its crystal structure (36)
and optimized at the DFT/B3LYP/6-311G** level. This protonated structure
features the R conﬁguration and a half-chair conformation of rings B and C.
The dihedral angle between rings A and D is 158. The molecular docking
program AutoDock3.05 (37) was employed to probe the possible SPD-
binding sites of the energy-minimum conformations of the D1 and D2
receptors derived from the MD trajectories.
RESULTS
3D structures of D1 and D2 receptors
Sequence alignment (Fig. S2 in the Supplementary Material)
indicates that the sequence identity and similarity are 21.8%
and 47.8%, respectively, for the TMs between rhodopsin
and the D1 receptor, 26.1% and 54.4% for the TMs between
rhodopsin and D2 receptor, and 44.5% and 66.4% between
the D1 and D2 receptors themselves. Based on the high
homology revealed by sequence alignments, the 3D models
of the D1 and D2 receptors were assembled taking the x-ray
crystal structure of bovine rhodopsin as a template. The
PROCHECK (38) statistics showed that 90% of the residues
in both the D1 and D2 models were in either the most favored
or in the additionally allowed regions of the Ramachandran
map (Fig. S3 in the Supplementary Material), suggesting
that the overall main chain and side chain structures are
all reasonable. The WHATIF (39) validation shows accept-
able RMS Z-scores. All of these data suggest that the models
obtained through our homology modeling are reasonable.
Two kinds of interaction networks are observed in D1 and
D2, i.e., aromatic residue clusters (Fig. S4) and hydrogen
bond (H-bond) network (Table S1). The presence of hydro-
phobic cluster and H-bond interaction with TM III and TM
VII in D1 could allow relative movement of TM VI. The
speciﬁc H-bonds cluster at the bottom of TM III and TM V is
observed consisting of R-3.50 and E-6.30. It is conserved in
both D1 and D2 receptors, and the DRY motif of TM III may
be relevant to the activation or inactivation of the receptor.
The extracellular loop 1 (EL-1) and extracellular loop 3
(EL-3) are typically short in all aminergic GPCRs. In con-
trast, EL-2 is signiﬁcantly longer and may reach into the active
site crevice and form a lid over the bound ligand. There is a
highly conserved disulﬁde bond between the conserved
Cys_e2 at the middle of EL-2 and Cys-3.25 at the beginning
of TM III. Thus in D1 and D2 receptors, the stretches of only
4–5 residues between Cys_e2 and extracellular end of TM5
are in an extended state to reach two sides. It is noteworthy
FIGURE 1 Overview of the SPD-D1/POPC/water sys-
tem. D1 is shown in ribbon; the hydrophobic chains of
bilayer lipids are labeled H; and the lipid carbonyl oxygen
atoms, choline N atoms, and P atoms are represented in a
space ﬁll model (labeled P), and water as W; the 3-D size
of the whole system was also labeled. The SPD in binding
site was ampliﬁed and shown in a stick model.
D1 Agonist and D2 Antagonist Dual Effect of SPD 1433
Biophysical Journal 93(5) 1431–1441
that there are 13 residues in the EL-2 loop of the D2 receptor,
whereas 26 residues exist in the EL-2 loop of the D1
receptor. The main difference in EL-2 mainly comes from
the upstream preceding conserved Cys_e2 (Fig. S2), which is
far away from the active site crevice. In addition, there are
six residues longer in the EL-3 of the D1 receptor than that of
the D2 receptor. Though the lengths of EL-2 and EL-3 are
different, they are ﬂexible and function as the conformational
switch to catch the outcoming ligands (see the discussion in
the next paragraph).
Open-closed conformational changes of free
D1 and D2
The MD simulations of the free D1 and D2 systems showed
that, for all of the systems, the temperature, mass density,
and volume are relatively stable after 2 ns. About then, the
ﬂuctuation scale became much smaller for both the RMS
deviations of the Ca atoms and potential energies (Fig. 2) of
the two simulation systems, indicating that the molecular
systems were well behaved thereafter.
When analyzing the MD trajectories, a striking ‘‘open-
closed’’ conformational change is observed from the extracel-
lular side for both the D1 and D2 receptors, as demonstrated
in Fig. 3. Further examination reveals that such an ‘‘open-
closed’’ event can be attributed mainly to large conforma-
tional changes in the EL-2 and EL-3, coupled with the
connecting TM helices. Typically, EL-2 and EL-3 act as
‘‘lips’’ of mouth-like entrances of the binding sites of these
two receptors. This can be demonstrated by the ﬂuctuations
of critical distance between K-167 at EL-2 and E-302 at EL-
3 (K-167-E-302 pairing), which is an objective monitor of
the width of the entrance. The open and closed conforma-
tions are shown in the dotted lines in Fig. 2. Taking D1 as an
example, the opening event at ;2630 ps for the ‘‘mouth’’
corresponds to changes in the K-167-E-302 pairing distance
(Fig. 4 A), which reaches one of the ‘‘peak’’ points as shown
in Fig. 6. As time proceeds, the ‘‘mouth’’ becomes gradually
closed at ;4210 ps and the distance between K-167-E-302
decreases to a local minimum. Such synchronization
between the ‘‘open-closed’’ conformational changes of the
whole D1 receptor and peak-minimum distance changes of
K-167-E-302 (Fig. 4 A) occurred three times during our 10-
ns MD simulations. Quite similar open-closed conforma-
tional changes were also seen for the free D2 (Fig. 3 B).
These dynamic properties suggest that there are at least two
distinct conformations for both D1 or D2, and the sponta-
neous oscillation between these two conformational states
appears to be an intrinsic phenomenon. Our observation is in
agreement with experimental mutagenesis studies in which it
was postulated that GPCRs exist in an equilibrium between
two interchangeable conformational states (40,41). One of
the obvious advantages of this type of dynamical behavior of
the binding site entrances (open-closed) is that it enables the
receptors to easily capture different ligands (agonists and
antagonists) or different conformations of a ligand, as will be
discussed later.
Tracing the MD trajectory of both the D1 and D2 receptors
revealed a portion of the atomic-level mechanism of the
open-closed motion. A hydrogen-bond (H-bond) network
exists between the charged side chains of K-167 and E-302.
At the beginning of MD simulation, the positively charged
side chain of K-167 forms direct H-bonds and two indirect
(water-bridged) H-bonds with the negatively charged side
chain of E-302 (Fig. 5 A). As the simulation proceeds, the
side chain of the E-302 turns away from K-167, breaking the
H-bond network. At ;2630 ps, all of the H-bonds between
K-167 and E-302 are gone. Meanwhile, K-167 gradually
approaches D-173 of EL-2, forming a new H-bond network
via water bridges (Fig. 5 B) which lasts;1 ns. K-167-E-302
switches back to the pairing state similar to that in Fig. 5 A,
and the H-bond network is restored. K-167 changes partners
frequently, either E-302 or D-173, staying with D-173 when
the ‘‘mouth’’ is open and with E-302 when the ‘‘mouth’’ is
closed. Therefore, the H-bond network between K-167 and
E-302 seems to act as a ‘‘bolt’’—its position controls
whether the ‘‘mouth’’ is open or closed.
Binding conformations of SPD in the
D1 and D2 receptors
To identify the most probable binding conformations of SPD
to the D1 and D2 receptors, 10 potential binding conformation
FIGURE 2 Energy changes alongMD
simulations. (A) D1 simulation system.
(B) D2 simulation system. Ten conforma-
tions shown in dotted line were identiﬁed
with two criteria: lower potential energy
andobviousgeometricaldifferenceamong
different conformations. Among them,
the conformations at 2630 ps in the MD
trajectory of the unligandedD1 and that at
3310 ps in the MD trajectory of un-
liganded D2 have the lowest binding
energies toward SPDandwere selected as
the conformations most probably active.
1434 Fu et al.
Biophysical Journal 93(5) 1431–1441
candidates of DRs were identiﬁed from each of the MD
trajectories of the unliganded D1 and D2 receptors (dotted
lines in Fig. 2) with two criteria: lower potential energy and
obvious geometrical difference among different conforma-
tions. Then SPD was docked into the binding cavities of
these 10 conformations of each receptor and the binding
energies were estimated by means of AutoDock3.05 (37).
Both the binding mode and binding afﬁnity between SPD
and DRs were used to guide the selection of the conforma-
tion that is most likely to be active. From among 10
candidates, the conformations were selected as the possible
conformation candidates if their main binding modes are in
agreement with known mutagenesis experiments. From these
possible conformation candidates, the conformation having
the lowest binding energy toward SPD was selected as the
conformations most likely to be active for each DR. The
predicted lowest binding free energy of SPD for D1 is12.8
kcal/mol and 11.7 kcal/mol, respectively. Although there
are deviations between the experimental value (10.8 kcal/
mol and 9.6 kcal/mol) (42–45) and predicted data, the
general trend observed in predicated binding free energies is
that SPD binds to D1 more strongly than to D2. The errors in
predicting binding afﬁnities mainly come from the homol-
ogy models of DRs and the imperfect empirical parameters
in AutoDock 3.05 for estimating binding afﬁnity.
Dual action mechanism of SPD with dopamine
D1 and D2 receptors
The structural determinant of pharmacological speciﬁcity
of SPD
The dynamics of the interactions between SPD and D1 or D2
was investigated to understand the agonistic and antagonistic
mechanism of SPD.
The distances between the key residues in the active sites
were monitored and used to delineate the dynamical change
of the active site among the bound complexes. Most dis-
tances ﬂuctuate a little bit in complexes SPD-D1. It shows
that SPD packs well with the side chains of residues in the
binding cavity of D1. In the SPD-D2 complex, there is an
interesting conformational change around the ligand. The
side chains of F-6.52 and H-6.55 come near the aromatic
rings A and D of SPD, apparently induced by hydrophobic
interactions among these groups and the bending of rings A
and D toward side chains of F-6.52 and H-6.55. There is also
an electrostatic attraction between the protonated side chain
of H-6.55 and the electron-rich group of ring A and atom
O2 of SPD (Fig. 6 D). The conformational bending of SPD
and the aromatic packing with the side chains of F-6.52
and H-6.55 appear to hold SPD against helix VI, constrain-
ing it after SPD binding. In comparison, there is no such
FIGURE 3 Representative conforma-
tions of the D1 (A) and D2 (B) receptors
during the open-closed process of the
binding site as observed from MD simu-
lations. A dashed arrow line indicates the
position of the ‘‘mouth’’, and a double
arrow dashed line shows the ‘‘mouth’’
opening. All of the conformations are
shown in the style of molecular surface
colored by electrostatic potential. The
red color stands for negative electrostatic
potential, and the blue for positive
potential.
FIGURE 4 Distance ﬂuctuations during
the MD simulations. (A) Distance from Nz
of K-167 (EL-2) to Cd of E-302 (EL-3) of
the D1 receptor; (B) distance from Cg of
D-178 (EL-2) to the centroid of the aro-
matic side chain of Y-408 (EL-3) of the D2
receptor. The open and closed conforma-
tions in Fig. 3 are shown in the dotted lines
in Fig. 2.
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conformational packing in the dynamic SPD-D1 complex, so
we consider this packing effect in the dynamic SPD-D2 com-
plex to be a structural determinant in the antagonism of SPD
with the D2 receptor, which will be described in detail later.
The agonistic and antagonistic conformations of SPD
There is only a small difference between the initial confor-
mations of SPD in the complexes with D1 and D2. By mutual
conformational adjustment during the ﬁrst ;5 ns of dynam-
ics, the conformation of SPD in the D2 binding cavity
becomes quite different from that in the D1 binding cavity
(Fig. 6, C and D). The ﬁrst adjustment was to the dihedral
angle between rings A and D. In the SPD-D2 complex, ring A
of SPD becomes almost perpendicular to ring D (dihedral
angle of 98), whereas the relative position of these two rings
in SPD still maintains planarity (dihedral angle of 150) in the
SPD-D1 complex. The second adjustment is reﬂected in the
different interactions between SPD with D1 and D2. As
shown in Fig. 6, the interactions between ring A of SPD and
the surrounding residues of D1 are mainly aromatic stacking
with the side chains of W-3.28, W-7.40, and W-7.43, plus
direct hydrogen bonding between the hydroxyl group on ring
A of SPD with Nj1 of W-3.28 (Fig. 6, C and E). In the SPD-
D2 complex, ring A of SPD has much stronger electrostatic
and hydrogen-bonding interactions with the protonated
H-6.55. The role of H-6.55 in stabilizing the bent SPD con-
formation in the D2 binding cavity becomes more important
because the N-6.55 at the same position in the D1 receptor is
not involved in any interactions with SPD.
Energies of the agonistic and antagonistic conformations
of SPD
We next investigated the energetics of the different bioactive
conformations of SPD in the different receptors, D1 and D2.
Quantum mechanical methods were employed to calculate
FIGURE 5 Hydrogen-bonding network among K-167,
D-173, E-302, and bridging water molecules in D1.
FIGURE 6 Binding modes of SPD in the D1 (A, C, and E) and D2 (B, D, and F) receptors. (A and B) The models of D1-SPD and D2-SPD. The active sites
were displayed as an electrostatic surface. (C andD) The important residues in the active sites of two complexes and SPD were rendered in stick representation.
(E and F) Schematic depiction of the main interactions between SPD with D1 and D2.
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molecular energies at the DFT/B3LYP/6-311G** level using
the Gaussian 98 program. The transition state conformation
of SPD between the agonistic and antagonistic conforma-
tions was located by the synchronous transit-guided quasi-
Newton methods (46) at the same level. Fig. 7 shows that
there is only a small energy barrier, 1.55 kcal/mol, between
the conformation of SPD in the D1 complex and the transi-
tion state conformation. The energy barrier between the con-
formation of SPD in the D2 complex and the transition state
conformation is 1.02 kcal/mol. These small energy differ-
ences demonstrate that the transition of SPD from the agonist
conformation to antagonist one is relatively facile. In other
words, SPD intrinsically has the capacity for dual functional
when associating with different DRs (D1 and D2).
Dynamical helix movement of the D1 receptor
upon SPD binding
In corresponding to the agonizing and antagonizing effects
of SPD, the TM helices of D1 and D2 take different extents
of motion. Taking the radius of gyration (Rg) as an example
(Fig. 8), the Rg of helices 1–7 in the SPD-D1 complex
gradually increases after ;3.0 ns and maintains a value of
1.775 nm from there until the end of the MD simulations. In
comparison, the Rg value of the SPD-D2 complex changes
slightly and maintains almost the same value as for the free
D2 receptor. Usually, the larger the Rg, the greater the extent
of the range of motion of the structure. The essential dynamics
analyses (47) performed on the complete MD trajectories of
the complexes helped us locate the most drastic motions
among helices. Two projected structures representing the
minimal and maximal amplitudes along the ﬁrst eigenvector
were selected and superimposed with each other (Fig. 9). The
relative motion among helices is different before and after
SPD binding in two receptors. In comparison with the SPD-
D2 complex, the binding of SPD to the D1 receptor (Fig. 9, A
versus C) results in the outward movement of seven TM
helices, especially TM6 and TM7, SPD-D1 complex is quite
relaxed. Among seven TM helices in the SPD-D1 complex,
TM6 and TM7 have the largest outward movement toward
the surrounding lipids (Fig. 9 A). On the other hand, the
SPD-D2 complex is quite conservative (Fig. 9, B and D) in
the motion of its helices. The dramatic movement of the
TM6-TM7 helices in the SPD-D1 complex appears to result
from the agonistic effect of SPD and distally propagates into
the intracellular end.
DISCUSSION
In this article we integrated homology modeling, MD sim-
ulation, automated docking, and density function theory to
understand the agonistic and antagonistic mechanism of SPD
and the activation process of the D1 receptor. So far, only the
structure of the bovine rhodopsin receptor was characterized
in the GPCR family. The identities between rhodopsin and
DRs D1 and D2 are ;25%. Though we carefully built D1
and D2 models and checked them by several programs of
structural validation and all available experimental data, the
models are still fuzzy. Furthermore, the timescale of our MD
simulations is short compared to the real biological process
of DRs. However, the current models are supported by most
known mutagenesis experiments, and our MD simulations
give the trend of the motion of the proteins. Since it is very
difﬁcult to characterize the structure of membrane protein
and its dynamical characteristic experimentally, it is a useful
complement for investigation of structural and functional
characteristic of the GPCR family and provides clues in
understanding the signal transduction process of DRs. In
particular, the obtained agonistic and antagonistic mecha-
nism of SPD can provide practical guidance for the design of
dual function lead compounds for D1/D2 receptors.
Interpretation of mutation data
Without high resolution structural information for the D1 and
D2 receptors, site-directed mutagenesis is usually employed
to explore the molecular mechanism of receptor activation
and signal transduction by ligand binding. To date, several
residues in either the D1 or D2 receptors have been revealed
to be critical for ligand binding. For example, D-3.32
(D-3.32G, D-3.32N, and D-3.32C) has been shown to be
critical to SPD binding for both the D1 and D2 receptors via
mutagenesis studies (5,6). Consistent with experimental
data, our models for both SPD complexes with the D1 and
D2 receptors demonstrate that D-3.32 acts as a hydrogen-
bond acceptor and forms electrostatic interactions with the
protonated SPD. Our complex models also show that the
side-chain hydroxyl group of either S-5.42 or S-5.46 forms a
hydrogen-bond with the hydroxyl group on ring D of SPD in
both the D1 and D2 complexes. Removing the hydroxyl
group of S-5.42 or S-5.46 will undoubtedly reduce the
binding afﬁnity of SPD with these two DRs. Cox et al. (40)
FIGURE 7 Energy barrier between the agonistic and antagonistic con-
formers of SPD calculated with B3LYP/6311g**. The calculated energy is
1.55 kcal/mol after the zero-point vibrational energy (ZPVE) correction.
D1 Agonist and D2 Antagonist Dual Effect of SPD 1437
Biophysical Journal 93(5) 1431–1441
and Tomic et al. (2) reached the same result on these two
residues via S-5.42A and S-5.46A mutations and related
functional studies. The importance of W-7.40 and W-7.43 in
the D1 receptor can be attributed to their involvement in
aromatic packing with rings A and B of SPD (Fig. 6). This is
why the W-7.40A and W-7.43A mutations performed by
Roth et al. (48) resulted in a decrease in binding afﬁnity of
the D1 receptor with its agonists. Our SPD-D2 complex
model and its dynamic properties have illustrated why the
D2 receptor is antagonized by SPD, that is, because elec-
trostatic interactions with the protonated H-6.55 and the
aromatic stacking with F-6.52 made it difﬁcult for helix VI
and its neighbors to move. Such a move of interaction is in
accord with the ﬁndings of Woodward et al. and others (49–
51): H-6.55C and H-6.55L mutations caused a remarkable
decrease in antagonist binding of the D2 receptor. Combined
with these experimental results, it can be inferred that
residues such as D-3.32, S-5.42, S-5.46, S-3.36, H-6.55,
W-7.40, and W-7.43 should be structural determinants for
the pharmacological speciﬁcity of the dual actions of SPD
against the D1/D2 receptors.
Proposed signal transduction model of the
D1 receptor
Based on our structural modeling and MD simulations, a
stepwise signal transduction model of D1 was proposed (Fig.
10). Since the model of D1 was built based on the bovine
rhodopsin, which has low identity with DRs (;25%), and
the MD simulation is short compared with the real biological
process of D1 motion, we should say that this model is
somewhat uncertain. However, our model and simulations
were supported by most known mutagenesis experiments. It
provides some useful information/clues for researchers who
investigate the activation process of the GPCR family.
Further biophysical experiments are needed to test and
improve this model.
Typically, the D1 receptor adopts the inactive state R
through its intramolecular interaction and transits between
several energy minima conformations by molecular thermo-
dynamic motion. As the protonated SPD diffuses to the
extracellular mouth of the binding cavity of the D1 receptor,
a kind of electrostatic signal is transmitted to the molecular
surface of D1 and promotes the disruption of the K-167-E-
302 salt bridge. The electrostatic attraction between the
negatively charged region of the D1 receptor and positively
charged SPD assists in their initial association (Rt1 state).
FIGURE 8 Time-dependent Rg of the four models. (A) D1 and D1-SPD. (B) D2 and D2-SPD.
FIGURE 9 Largest anharmonic motions of the TMhelices (viewed intracel-
lularly) identiﬁed by essential dynamics analysis. (A) D1-SPD. (B) D2-SPD.
For comparison, the minimum motion of helices is shown in green, and the
maximum is colored in purple for both complexes.
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Further nestling of SPD into the binding cavity brings about
a dramatic outward movement toward lipid in TM6 and TM7
(Rt2 state). Through this induced conformational shift, the
receptor is activated and couples with the a-subunit of the
intracellular G-protein (R* state), transferring extracellular
signals to the intracellular G-protein. This stepwise signal
transduction model was supported by the currently accepted
postulate about the activation of GPCRs; that is, GPCRs
exist in an equilibrium between two interchangeable confor-
mational states, namely a dynamic R state and an activated
R* state (40,41), and there should be considerable confor-
mational movement in TM6 and TM7 after agonist binding
(17,19,52–54).
Signiﬁcance to future drug discovery targeting the
D1/D2 receptors
DRs remain attractive and challenging drug targets when
searching for potential therapeutics of psychological diseases
(4,41). Our demonstration of a potential molecular mecha-
nism for the dual function of SPD as an agonist of D1 and an
antagonist of D2 provides practical guidance in the design of
novel lead compounds. We already have made some prom-
ising progress along these lines via our screening for novel
SPD-like compounds combined with experimental testing
(W. Fu, W. Zhu, and H. Jiang, unpublished data). Our com-
putational results suggest that any small compound able to
pack well with W-7.40 and W-7.43 in the D1 receptor and
pack with H-6.55 in D2 may exhibit dual activity against the
D1 and D2 receptors, as does SPD.
CONCLUSIONS
We report herein four 10-ns MD simulations of the un-
liganded D1 and D2 receptors and D1-SPD and D2-SPD
complexes, all simulated in a lipid bilayer membrane.
Distribution of the electrostatic potentials on the molecular
surface and the conformational ‘‘open-closed’’ transition of
the D1 and D2 receptors were addressed by the MD
simulations. The K-167_EL-2-E-302_EL-3 salt bridge in the
D1 receptor plays an important role in the conformational
change of extracellular domain and in the binding of SPD.
The binding of SPD to the D1 receptor causes a structural
relaxation, which is an early step in the activation of GPCRs.
Major and signiﬁcant structural differences were seen in the
TM6 and TM7 domains in the D1-SPD complex. In par-
ticular, TM6 exhibits the most signiﬁcant motion during D1
receptor activation.
A detailed molecular level mechanism of the D1 agonistic
and D2 antagonistic action of SPD has been delineated. Our
models indicate that the agonistic binding site in D1 and the
antagonistic binding site in D2 share a common binding
region in the structurally aligned receptors. However, SPD
takes on two different bioactive conformations, one in the
agonistic complex with D1 and the other in the antagonistic
complexes with D2. The structural determinants for the
pharmacological speciﬁcity of dual action of SPD were
uncovered from the modeling and simulations. Combined
with all the available experimental data, it can be concluded
that residues H-6.55, W-7.40, and W-7.43 must be structural
determinants for differentiating the pharmacological dual
speciﬁcities of SPD for the D1 and D2 receptors. Finally, a
potential signal transduction mechanism of the D1 receptor
was proposed. Further mutagenesis and biophysical exper-
iments are needed to test and improve our dual action
mechanism of SPD and stepwise signal transduction model.
Our results have already been used in database searching
to identify new candidate compounds with dual actions
based on our identiﬁed D1 agonist and D2 antagonist confor-
mations. Several molecular leads for the eventual treatment
FIGURE 10 Signal transduction model of the D1 receptor by an SPD-like agonist. R represents the dynamic state, Rt1 and Rt2 are transitional states before
receptor activation, and R* refers to the activated state ready to couple with intracellular G-proteins.
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of diseases affecting the central nervous system, such as
schizophrenia, have been selected and are undergoing further
experimental testing (W. Fu, W. Zhu, and H. Jiang, unpub-
lished data).
SUPPLEMENTARY MATERIAL
To view all of the supplemental ﬁles associated with this
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